SCHEMBL3169403

SCHEMBL3169403

O=C(c1ccc(S(=O)(=O)Nc2nccs2)cc1)N1CCCC(Cc2ccc(F)cc2)C1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
CCR3 P51677 1/20 0.51
CYP1A2 P05177 1/20 0.50
POLB P06746 1/20 0.50
CYP2C9 P11712 1/20 0.50
HPGD P15428 1/20 0.50
CYP2C19 P33261 1/20 0.50
ALDH1A1 P00352 2/20 0.48
HTT P42858 2/20 0.48
CA1 P00915 1/20 0.48
GAA P10253 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
SCN1A P35498 1/20 0.47
SCN8A Q9UQD0 1/20 0.47
SCN9A Q15858 2/20 0.47
SCN3A Q9NY46 5/20 0.47
PSEN1 P49768 1/20 0.46
PSEN2 P49810 1/20 0.46
APH1B Q8WW43 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3162724 0.90 SCN1A (0.50) MEN1KMT2AALDH1A1HTTSCN1A
SCHEMBL3172220 0.89 ALDH1A1 (0.56) ALDH1A1HTTSCN1ASCN8AKDM4E
SCHEMBL3158834 0.88 KMT2A (0.51) MEN1KMT2AALDH1A1HTTCA1
SCHEMBL3168335 0.88 MEN1 (0.48) MEN1KMT2AALDH1A1HTTSCN9A
SCHEMBL3163044 0.88 KMT2A (0.51) MEN1KMT2AALDH1A1HTTSCN9A
SCHEMBL3159054 0.86 SCN3A (0.57) MEN1KMT2AALDH1A1HTTCA1
SCHEMBL3158666 0.84 SCN9A (0.47) MEN1KMT2AALDH1A1HTTCA1
SCHEMBL3153864 0.83 SCN1A (0.52) KMT2AALDH1A1HTTSCN1ASCN8A
SCHEMBL3163482 0.83 KMT2A (0.54) MEN1KMT2APOLBALDH1A1HTT
SCHEMBL3262317 0.81 ALDH1A1 (0.54) MEN1KMT2AALDH1A1HTTSCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8741934-B2 Inhibitors of ion channels PFIZER LIMITED (GB) 2014-06-03 US disclosed
US-20130072471-A1 Inhibitors of Ion Channels MARRON BRIAN EDWARD (US) 2013-03-21 US disclosed
US-8357711-B2 Heterocyclic sulfonamides as inhibitors of ion channels PFIZER LIMITED (GB) 2013-01-22 US disclosed
EP-1995241-B1 Inhibitors of ion channels ICAGEN INC (US) 2010-03-17 EP disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US disclosed
EP-1995241-A1 Inhibitors of ion channels ICAgen, Incorporated (US) 2008-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072471-A1 Inhibitors of Ion Channels TRPV1, TRPV5, TRPA1 MEN1 4729/4885KMT2A 1920/4885CCR3 2043/4885
US-20090143358-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 MEN1 4729/4885KMT2A 1920/4885CCR3 2043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.